Comparison of neoadjuvant chemoradiotherapy versus chemoradiotherapy plus immunotherapy for esophageal squamous cell carcinoma in a real-world multicenter cohort: a propensity score matching study.
Esophageal squamous cell carcinoma
Immunochemotherapy
Neoadjuvant chemoradiotherapy
Neoadjuvant immunotherapy
Postoperative complications
Treatment response
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
02
08
2024
accepted:
10
10
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
Neoadjuvant chemoradiotherapy combined with immunotherapy (NICRT) is a new neoadjuvant treatment approach that has raised concerns regarding potential challenges in surgery and postoperative complications. This study aimed to compare the efficacy and safety of neoadjuvant chemoradiotherapy (NCRT) and NICRT for the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC). We retrospectively analyzed 291 patients with locally advanced ESCC who underwent neoadjuvant therapy and esophagectomy at three centers between January 2019 and September 2023 and added the data from PALACE-1 for the analysis, Among these patients, 248 and 61 patients received NCRT and NICRT, respectively. Propensity score matching (PSM) was used to balance the potential bias. After the PSM,the rate of a pathological complete response (pCR) in the NCRT group was not significantly different from that in the NICRT group (46.90% vs 36.36%, P = 0.180). There were no significant differences in the tumor regression grade (TRG) and positive lymph node pCR rates between the two groups (P = 0.233 and P = 0.354, respectively). Treatment-related toxicities and postoperative complications were not significantly different between the NCRT group and the NICRT group (P = 0.199, P = 0.284). Compared with NCRT, NICRT did not lead to the better treatment efficacy. There were no significant differences was observed in the incidence of treatment-related toxicities and postoperative complications.
Sections du résumé
BACKGROUND
BACKGROUND
Neoadjuvant chemoradiotherapy combined with immunotherapy (NICRT) is a new neoadjuvant treatment approach that has raised concerns regarding potential challenges in surgery and postoperative complications. This study aimed to compare the efficacy and safety of neoadjuvant chemoradiotherapy (NCRT) and NICRT for the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC).
METHODS
METHODS
We retrospectively analyzed 291 patients with locally advanced ESCC who underwent neoadjuvant therapy and esophagectomy at three centers between January 2019 and September 2023 and added the data from PALACE-1 for the analysis, Among these patients, 248 and 61 patients received NCRT and NICRT, respectively. Propensity score matching (PSM) was used to balance the potential bias.
RESULTS
RESULTS
After the PSM,the rate of a pathological complete response (pCR) in the NCRT group was not significantly different from that in the NICRT group (46.90% vs 36.36%, P = 0.180). There were no significant differences in the tumor regression grade (TRG) and positive lymph node pCR rates between the two groups (P = 0.233 and P = 0.354, respectively). Treatment-related toxicities and postoperative complications were not significantly different between the NCRT group and the NICRT group (P = 0.199, P = 0.284).
CONCLUSION
CONCLUSIONS
Compared with NCRT, NICRT did not lead to the better treatment efficacy. There were no significant differences was observed in the incidence of treatment-related toxicities and postoperative complications.
Identifiants
pubmed: 39433841
doi: 10.1038/s41598-024-76097-3
pii: 10.1038/s41598-024-76097-3
doi:
Types de publication
Journal Article
Multicenter Study
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
24738Subventions
Organisme : National Natural Science Foundation of China
ID : NSFC82073345
Informations de copyright
© 2024. The Author(s).
Références
Ajani, J.A. et al. Esophageal and esophagogastric junction Cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J. Natl. Comprehens. Cancer Netw. 17(7), 855–883 (2019).
Yang, H. et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase III multicenter, randomized, open-label clinical trial. J. Clin. Oncol. 36(27), 2796–2803 (2018).
doi: 10.1200/JCO.2018.79.1483
pubmed: 30089078
pmcid: 6145832
Zhang, B. et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun. 40(12), 711–720 (2020).
doi: 10.1002/cac2.12119
Shah, M. A. et al. KEYNOTE-975 study design: A phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 17(10), 1143–1153 (2021).
doi: 10.2217/fon-2020-0969
pubmed: 33533655
pmcid: 7927908
Zhang, W. et al. Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist 26(7), e1110–e1124 (2021).
doi: 10.1002/onco.13797
pubmed: 33893689
pmcid: 8265339
Doki, Y. et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386(5), 449–462 (2022).
doi: 10.1056/NEJMoa2111380
pubmed: 35108470
Li, C. et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur. J. Cancer 144, 232–241 (2021).
doi: 10.1016/j.ejca.2020.11.039
pubmed: 33373868
van den Ende, T. et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A single-arm phase II feasibility trial (PERFECT). Clin. Cancer Res. 27(12), 3351–3359 (2021).
doi: 10.1158/1078-0432.CCR-20-4443
pubmed: 33504550
Lee, S. et al. A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC). Ann. Oncol. 30 (2019).
Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16(9), 563–580 (2019).
doi: 10.1038/s41571-019-0218-0
pubmed: 31092901
Low, D. E. et al. International consensus on standardization of data collection for complications associated with esophagectomy. Ann. Surg. 262(2), 286–294 (2015).
doi: 10.1097/SLA.0000000000001098
pubmed: 25607756
Dindo, D., Demartines, N. & Clavien, P.-A. Classification of surgical complications. Ann. Surg. 240(2), 205–213 (2004).
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Shapiro, J. et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol. 16(9), 1090–1098 (2015).
doi: 10.1016/S1470-2045(15)00040-6
pubmed: 26254683
Wan, T. et al. The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: Systematic review and meta-analysis of 21 studies. Ann. Surg. Oncol. 26(5), 1412–1420 (2019).
doi: 10.1245/s10434-018-07147-0
pubmed: 30805807
Integrated genomic characterization of oesophageal carcinoma. Nature 541(7636), 169–175 (2017).
doi: 10.1038/nature20805
Zhang, L. et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am. J. Hum. Genet. 96(4), 597–611 (2015).
doi: 10.1016/j.ajhg.2015.02.017
pubmed: 25839328
pmcid: 4385186
Yarchoan, M. et al. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer 17(4), 209–222 (2017).
doi: 10.1038/nrc.2016.154
pubmed: 28233802
pmcid: 5575801
Brandmaier, A. & Formenti, S. C. The impact of radiation therapy on innate and adaptive tumor immunity. Semin. Radiat. Oncol. 30(2), 139–144 (2020).
doi: 10.1016/j.semradonc.2019.12.005
pubmed: 32381293
Reynders, K. et al. The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant. Cancer Treat. Rev. 41(6), 503–510 (2015).
doi: 10.1016/j.ctrv.2015.03.011
pubmed: 25872878
pmcid: 4816218
Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12(12), 860–875 (2012).
doi: 10.1038/nrc3380
pubmed: 23151605
Low, D. E. et al. Benchmarking complications associated with esophagectomy. Ann. Surg. 269(2), 291–298 (2019).
doi: 10.1097/SLA.0000000000002611
pubmed: 29206677
Cools-Lartigue, J. et al. An international cohort study of prognosis associated with pathologically complete response following neoadjuvant chemotherapy versus chemoradiotherapy of surgical treated esophageal adenocarcinoma. Ann. Surg. 276(5), 799–805 (2022).
doi: 10.1097/SLA.0000000000005619
pubmed: 35861351
von Döbeln, G.A. et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. Dis. Esophagus 32(2) (2018).
Ma, J. et al. Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer. Front. Oncol. 13 (2023).